Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $5.00 by Analysts at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) had its target price reduced by HC Wainwright from $12.00 to $5.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($1.03) EPS, FY2024 earnings at ($4.39) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($3.35) EPS.

INO has been the subject of several other research reports. Oppenheimer decreased their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday. Royal Bank of Canada decreased their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $38.00.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock opened at $4.06 on Monday. Inovio Pharmaceuticals has a 1-year low of $3.85 and a 1-year high of $14.75. The firm’s fifty day simple moving average is $5.61 and its 200-day simple moving average is $8.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Barclays PLC boosted its position in shares of Inovio Pharmaceuticals by 282.6% in the third quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 25,116 shares during the period. Geode Capital Management LLC raised its stake in Inovio Pharmaceuticals by 6.7% during the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares during the last quarter. Wellington Management Group LLP bought a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at $379,000. State Street Corp grew its position in Inovio Pharmaceuticals by 11.7% in the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after purchasing an additional 51,414 shares during the last quarter. Finally, Atom Investors LP acquired a new stake in Inovio Pharmaceuticals in the 3rd quarter worth $103,000. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.